Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of IBI310 Monotherapy or in Combination with Sintilimab in Advanced Solid Tumors
NCT03545971Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Sep 2018
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBI310 in solid tumor, melanoma and urothelial carcinoma (UC) (8 cohorts), sponsored by Innovent Biologics. Primary endpoint: Adverse Events up to 24 months. Started Sep 2018; status: completed.
02
Drugs
IBI310
03
Conditions
solid tumormelanomaurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03545971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03545971.